Clinical trial NCT04569318: A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive LEDINBIO Proof-Of-Concept Device
Official title: A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive LEDINBIO Proof-Of-Concept Device
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cataract
Lead sponsor: Edinburgh Biosciences Ltd
Sponsor class: INDUSTRY
Collaborators: name: Onorach Clinical
First posted: 2020-09-29
Enrollment: 11
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single arm interventional study
Primary purpose: TREATMENT

Brief summary: Single arm proof-of-concept trial to evaluate the safety and efficacy of the LEDINBIO PoC Device in the treatment of cataract.

Detailed description: Single arm, single site proof-of-concept trial to evaluate the safety and efficacy of the LEDINBIO PoC Device, with 8 x 15-minute twice-weekly treatments and 3 month safety follow-up, in the treatment of cataract.

Only one of the subject's eyes will be treated during the study. In addition, spectral data (fluorescent emission) will be collected using the device to monitor the progress of the treatment, and to determine the suitability of these measurements for future clinical diagnoses

Eligibility criteria: Inclusion Criteria:

1. Subject diagnosed with nuclear sclerotic (NS) lens opacities cataract, LOCS III grade 1 to 3 (moderate), as confirmed by the Investigator
2. Subject aged between 55 and 85 years of age (inclusive) at the time of consent
3. Best corrected visual acuity (BCVA) of 0.3 or worse due to cataract only
4. Subject whom the medical health history has been reviewed by the Investigator and medical records do not contraindicate the participation to the study
5. Subject who is judged suitable for the study after ophthalmic examination carried out by the Investigator
6. Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator - including being able to sit upright for at least 20 mins (duration of the treatment)

Exclusion Criteria:

1. Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalised by court or official order, or in a dependency relationship with sponsor, testing centre or investigator
2. Subject who had been clinically diagnosed with any eye diseases which may impact upon the treatment, or the subject's ability to be assessed after treatment
3. Subject with shallow anterior chamber
4. Subject who have had a fluorescence angiogram or any use of fluorescein within the last 3 days
5. Subject presenting eye infection or eye damage in either eye
6. Subject routinely using contact lenses
7. Planned replacement of crystalline lens with intraocular lens (IOL) implant within the planned study period
8. Any condition which could interfere with the subject's ability to comply with the study including participation in all study assessments and visits.
9. Subject who had undergone a treatment using photodynamic drugs within the last 30 days. (Including but not limited to methylene blue, toluidine blue, Visudyne®, Foscan, Photofrin or 5-aminolevulinic acid/ALA)
10. Subject diagnosed with any other health condition which, in the opinion of the Investigator, would pose a safety risk to the subject by participating in the study, or may interfere with or jeopardise the study evaluation, procedures or completion
11. Subject currently receiving treatment in another investigational study or has completed another investigational study within the last 30 days
12. Females who are pregnant or lactating
13. Females who are of childbearing potential (menses within the last 12 months) and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable contraceptive precautions may be included.

Primary outcomes:
measure: Safety: assessed by changes in the Local Ocular Tolerability (LOT) Visual Analogue Scale (VAS)
timeFrame: 20 weeks
measure: Efficacy: Cataract Grade
timeFrame: 5 weeks
Secondary outcomes:
measure: Change in cataract severity
timeFrame: 5 weeks
measure: Change in visual acuity
timeFrame: 5 weeks
measure: Change in light scatter
timeFrame: 5 weeks
measure: Change in functional impairment due to cataract
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Riga
country: Latvia
facility: Dr.Solomatina Acu Centrs
Study officials:
affiliation: Edinburgh Biosciences Ltd
name: Chief Executive
role: STUDY_CHAIR
References: